- BMS 303141
-
- $1.00 / 1g
-
2019-12-24
- CAS:943962-47-8
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 20kg
|
| | BMS 303141 Basic information |
| Product Name: | BMS 303141 | | Synonyms: | BMS 303141;BMS30314;3,5-dichloro-2-hydroxy-N-(4-Methoxybiphenyl-3-yl)benzenesulfonaMide;3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1'-biphenyl]-3-yl)benzenesulfonamide;3,5-Dichloro-2-hydroxy-N-(4-methoxy[1,1'-biphenyl]-3-yl)-benzenesulfonamide BMS 303141;BMS 303141, >=98%;3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide;CS-887 | | CAS: | 943962-47-8 | | MF: | C19H15Cl2NO4S | | MW: | 424.3 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 943962-47-8.mol |  |
| | BMS 303141 Chemical Properties |
| Boiling point | 591.5±60.0 °C(Predicted) | | density | 1.462±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: soluble20mg/mL, clear | | pka | 4.94±0.48(Predicted) | | form | powder | | color | white to beige | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months. |
| | BMS 303141 Usage And Synthesis |
| Description | BMS-303141 (943963-47-8) is a potent and selective ATP citrate lyase (ACL) inhibitor, IC50=0.13 μM. Inhibits lipid biosynthesis, IC50=8 μM in HepG2 cells.1,2?Reduces weight gain, lowers plasma cholesterol, triglycerides and glucose in high-fat-fed mice.2?A novel tool compound for exploring the potential of ACL inhibition as a target for metabolic disorders such as obesity and dyslipidemia.2?Impairs proliferation or induces death in androgen-depleted castration resistant prostate cancer cells.3?Reduces cell cycle progression in iBN cells.4 | | Uses | BMS-303141 has been used for inhibition of ATP citrate lyase in breast cancer cell lines. | | Definition | ChEBI: 3,5-dichloro-2-hydroxy-N-(2-methoxy-5-phenylphenyl)benzenesulfonamide is a member of biphenyls. | | Biochem/physiol Actions | BMS-303141 is a potent inhibitor of ATP citrate lyase (ACL). BMS-303141 inhibits lipid synthesis in HepG2 cells with an IC50 of 8 μM, and lowers plasma triglycerides in a murine hyperlipdemia model. | | storage | Store at -20°C | | References | 1) Li?et al. (2007),?2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors; Bioorg. Med. Chem.,?17?3208
2) Ma?et al.?(2009),?A novel direct homogeneous assay for ATP citrate lyase; J. Lipid Res.,?50?2131
3) Shah?et al.?(2016),?Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism; Oncotarget,?7?43713
4) Rhee and Dekoter (2017),?Regulation of Lipid Metabolism and Cell Cycle Progression by PU.1 in Myeloid Progenitor Cells; Blood,?130?2433 |
| | BMS 303141 Preparation Products And Raw materials |
|